• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp. - Common Stock (NQ:LEXX)

0.3910 -0.0053 (-1.34%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexaria Bioscience Corp. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
32 33 Next >
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Highlights Expanding Opportunities in GLP-1 Drug Market and Strategic Focus on DehydraTECH Integration
December 03, 2024
Via Investor Brand Network
Topics Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Highlights Expanding Opportunities in GLP-1 Drug Market and Strategic Focus on DehydraTECH Integration
December 03, 2024
Via CannabisNewsWire
Topics Intellectual Property
News headline image
Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs
November 26, 2024
Via ACCESSWIRE
News headline image
Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled
November 25, 2024
Via ACCESSWIRE
News headline image
Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study
November 14, 2024
Via ACCESSWIRE
News headline image
Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss
November 13, 2024
Via ACCESSWIRE
News headline image
Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments
November 07, 2024
Via ACCESSWIRE
Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study
October 24, 2024
DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing blood sugar groups 
Via TheNewswire.com
News headline image
ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria’s 12-Week GLP-1, Diabetes Animal Study
November 20, 2024
Via ACCESSWIRE
News headline image
Positive Partial 12-Week Blood Sugar Results from Lexaria’s GLP-1 Diabetes Animal Study
October 24, 2024
Via ACCESSWIRE
Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study
October 22, 2024
DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing weight loss groups 
Via TheNewswire.com
News headline image
Positive Partial 12-Week Body Weight Results from Lexaria’s GLP-1 Diabetes Animal Study
October 22, 2024
Via ACCESSWIRE
Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
October 16, 2024
Kelowna, British Columbia – October 16, 2024 – TheNewswire – Lexaria Bioscience Corp. (Nasdaq: LEXX; LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today announced... 
Via TheNewswire.com
Topics Regulatory Compliance
News headline image
Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing
October 09, 2024
Via ACCESSWIRE
News headline image
Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3
September 27, 2024
Via ACCESSWIRE
News headline image
Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
October 16, 2024
Via ACCESSWIRE
News headline image
Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
October 15, 2024
Via ACCESSWIRE
InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins Subject Dosing in Human Pilot Study #3 Evaluating Oral DehydraTECH-Processed Tirzepatide
October 09, 2024
Via Investor Brand Network
Topics Intellectual Property
InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Update on Growth of GLP-1 Market Space, Notes Potential for Oral Delivery
October 08, 2024
Via Investor Brand Network
Topics Intellectual Property
News headline image
Lexaria Updates Current GLP-1 Market
October 08, 2024
Via ACCESSWIRE
HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Continues to Strengthen Executive Team in Anticipation of ‘Strong Growth’ into 2025
October 01, 2024
Via Investor Brand Network
Topics Intellectual Property
News headline image
Lexaria Appoints Michael Shankman as Chief Financial Officer
October 01, 2024
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Begin Human Pilot Study #3 Evaluating DehydraTECH-Processed Tirzepatide
September 27, 2024
Via Investor Brand Network
Topics Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Begin Human Pilot Study #3 Evaluating DehydraTECH-Processed Tirzepatide
September 27, 2024
Via CannabisNewsWire
Topics Intellectual Property
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating ‘More Effective, Tolerable’ Oral Delivery of GLP-1 Drugs
September 20, 2024
Via Investor Brand Network
Topics Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires New CEO Amid Shift in Focus to Pharmaceutical Industry Collaboration and Operations
September 20, 2024
Via Investor Brand Network
Topics Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires New CEO Amid Shift in Focus to Pharmaceutical Industry Collaboration and Operations
September 20, 2024
Via CannabisNewsWire
Topics Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Demonstrates Continued DehydraTECH(TM)-Liraglutide Performance with Ongoing GLP-1 Diabetes Animal Study
September 17, 2024
Via Investor Brand Network
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing Market Potential with Unique Delivery Platform, GLP-1 Program
September 13, 2024
Via Investor Brand Network
Topics Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Shares Letter from Outgoing CEO
September 06, 2024
Via CannabisNewsWire
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
32 33 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap